VLS-01

About AtaiBeckley

AtaiBeckley is a newly formed, private biotech powerhouse in the psychedelics sector, headquartered in Berlin. It emerged from the merger of two established players, atai Life Sciences and Beckley Psytech, positioning it as a global leader with a deep pipeline targeting major depressive disorder and social anxiety disorder. The company is advancing novel formulations of compounds like mebufotenin and DMT through clinical trials, aiming to offer faster-acting and more effective alternatives to current standard-of-care treatments. Its strategy leverages decades of combined expertise in drug development to tackle a mental health market with significant unmet need and enormous economic burden.

About atai Life Sciences

AtaiBeckley, formed from the strategic combination of atai Life Sciences and Beckley Psytech, is a global biotech leader focused on transforming mental healthcare through novel psychedelic-derived therapeutics. Its core strategy employs a decentralized platform to identify, incubate, and fund subsidiary programs, de-risking development across a diversified pipeline. Key near-term catalysts include Phase 2 readouts for its lead programs—BPL-003 and VLS-01 in treatment-resistant depression and EMP-01 in social anxiety disorder—positioning it at the forefront of a potentially paradigm-shifting treatment modality.

Therapeutic Areas

Other Depression Drugs